Ness Therapeutics Inc. is a Canadian biotechnology company developing N001, a host-directed intranasal biologic designed to provide rapid, localized antiviral protection in the upper airway. N001 is being advanced as a dual-use defence and civilian medical countermeasure for respiratory viral threats, with potential application in pandemic preparedness, biodefence, healthcare protection, outbreak response, and public-health resilience.

The company has generated early product-specific feasibility data and has received Government of Canada support for key development activities. Ness is now preparing for IND/CTA-enabling execution, institutional financing, clinical-entry readiness, and strategic partnerships.

The Role

Ness is seeking a Chief Executive Officer to lead the company through its next stage of growth. The CEO will be responsible for corporate strategy, financing, partnerships, governance, and execution of the development plan for N001.

This ...